{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T02:22:36Z","timestamp":1785637356191,"version":"3.56.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpet.2025.103780","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:16:38Z","timestamp":1764000998000},"page":"103780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-4149","authenticated-orcid":false,"given":"Xenia L.","family":"Nastatos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-0001","authenticated-orcid":false,"given":"Elise A.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0505-1363","authenticated-orcid":false,"given":"Nial J.","family":"Wheate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jpet.2025.103780_bib1","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.3390\/s20185251","article-title":"Robot-aided systems for improving the assessment of upper limb spasticity: a systematic review","volume":"20","author":"de-la-Torre","year":"2020","journal-title":"Sensors (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103780_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638280400014576","article-title":"Spasticity: clinical perceptions, neurological realities and meaningful measurement","volume":"27","author":"Pandyan","year":"2005","journal-title":"Disabil Rehabil"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm0310-270","article-title":"Spasticity: a switch from inhibition to excitation","volume":"16","author":"Edgerton","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mus.20900","article-title":"Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief","volume":"37","author":"McClelland","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpet.2025.103780_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2377-9-59","article-title":"Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review","volume":"9","author":"Lakhan","year":"2009","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103780_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dmcn.14165","article-title":"Cannabinoids for the treatment of spasticity","volume":"61","author":"Nielsen","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103780_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/jnnp.2004.035972","article-title":"Clinical management of spasticity","volume":"76","author":"Thompson","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpet.2025.103780_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ctim.2017.08.010","article-title":"Cannabinoids for spasticity due to multiple sclerosis or paraplegia: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Rovare","year":"2017","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.jpet.2025.103780_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4737","article-title":"The management of spasticity in adults","volume":"349","author":"Nair","year":"2014","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jpet.2025.103780_bib10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40266-012-0034-z","article-title":"The pharmacological management of post-stroke muscle spasticity","volume":"29","author":"Bakheit","year":"2012","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib11","first-page":"168","article-title":"Active and passive characteristics of muscle tone and their relationship to models of subluxation\/joint dysfunction: part I","volume":"47","author":"Knutson","year":"2003","journal-title":"J Can Chiropr Assoc"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(97)00102-4","article-title":"Understanding and measurement of muscle tone as related to clinical muscle pain","volume":"75","author":"Simons","year":"1998","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.jpet.2025.103780_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0885-3924(94)90199-6","article-title":"Centrally acting skeletal muscle relaxants and associated drugs","volume":"9","author":"Waldman","year":"1994","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpet.2025.103780_bib14","series-title":"Reference Module in Neuroscience and Biobehavioral Psychology","article-title":"Spasm","author":"Ahmad","year":"2017"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpainsymman.2004.05.002","article-title":"Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review","volume":"28","author":"Chou","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/toxins10010034","article-title":"Azemiopsin, a selective peptide antagonist of muscle nicotinic acetylcholine receptor: preclinical evaluation as a local muscle relaxant","volume":"10","author":"Shelukhina","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.jpet.2025.103780_bib17","series-title":"Australian Medicines Handbook","year":"2020"},{"key":"10.1016\/j.jpet.2025.103780_bib19","series-title":"Pharmacology for the Physical Therapist","author":"Jobst","year":"2020"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/jnnp.69.2.143","article-title":"Botulinum toxin and spasticity","volume":"69","author":"Davis","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/16501977-2211","article-title":"Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen","volume":"49","author":"Ertzgaard","year":"2017","journal-title":"J Rehabil Med"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103780_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: pharmacological and interventional approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit Rev Phys Rehabil Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103780_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0929-6646(11)60033-8","article-title":"Pharmacotherapy of spasticity in children with cerebral palsy","volume":"110","author":"Chung","year":"2011","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200059030-00006","article-title":"Drugs used to treat spasticity","volume":"59","author":"Kita","year":"2000","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jpet.2025.103780_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/practneurol-2011-000155","article-title":"Spasticity: pathophysiology, evaluation and management","volume":"12","author":"Kheder","year":"2012","journal-title":"Pract Neurol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103780_bib26","first-page":"697","article-title":"Demystifying spasticity in primary care","volume":"65","author":"Milligan","year":"2019","journal-title":"Can Fam Physician"},{"issue":"6","key":"10.1016\/j.jpet.2025.103780_bib27","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s12325-020-01354-6","article-title":"Limited utility for benzodiazepines in chronic pain management: a narrative review","volume":"37","author":"Wright","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","article-title":"The religious and medicinal uses of Cannabis in China, India and Tibet","volume":"13","author":"Touw","year":"1981","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10681-004-4757-8","article-title":"Cannabinoids for the pharmaceutical industry","volume":"140","author":"Stott","year":"2004","journal-title":"Euphytica"},{"issue":"5","key":"10.1016\/j.jpet.2025.103780_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2020.052","article-title":"Prescribing medicinal cannabis","volume":"43","author":"Arnold","year":"2020","journal-title":"Aust Prescr"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users","volume":"25","author":"Hindocha","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics14020389","article-title":"\u201cThe two sides of the same coin\u201d\u2013medical cannabis, cannabinoids and immunity: pros and cons explained","volume":"14","author":"Khoury","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.jpet.2025.103780_bib33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41401-020-00530-2","article-title":"The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders","volume":"41","author":"Xin","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jpet.2025.103780_bib34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vu\u010dkovi\u0107","year":"2018","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103780_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/practneurol-2018-002137","article-title":"Cannabis and multiple sclerosis","volume":"19","author":"Ingram","year":"2019","journal-title":"Pract Neurol"},{"issue":"20","key":"10.1016\/j.jpet.2025.103780_bib36","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103780_bib37","series-title":"Cannabinoid Pharmacology","first-page":"67","article-title":"Cannabis pharmacology: the usual suspects and a few promising leads","author":"Russo","year":"2017"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.36118\/pharmadvances.2021.04","article-title":"Cannabidiol and the central nervous system: translating into clinics","volume":"3","author":"Saviano","year":"2021","journal-title":"Pharmadvances"},{"issue":"5","key":"10.1016\/j.jpet.2025.103780_bib39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jdcr.2017.06.012","article-title":"Medical marijuana for the treatment of vismodegib-related muscle spasm","volume":"3","author":"Yuan","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis","volume":"33","author":"Borgelt","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12954-020-00377-0","article-title":"Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)","volume":"17","author":"Lintzeris","year":"2020","journal-title":"Harm Reduct J"},{"issue":"11","key":"10.1016\/j.jpet.2025.103780_bib43","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11136-018-1958-5","article-title":"Evaluating the PROMIS-29 v2.0 for use among older adults with multiple chronic conditions","volume":"27","author":"Rose","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jpet.2025.103780_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ctcp.2019.03.013","article-title":"Change in young people\u2019s spine pain following chiropractic care at a publicly funded healthcare facility in Canada","volume":"35","author":"Manansala","year":"2019","journal-title":"Complement Ther Clin Pract"},{"key":"10.1016\/j.jpet.2025.103780_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2022.08.030","article-title":"Longitudinal changes in quality of life after ureteroscopy for nephrolithiasis","volume":"170","author":"Sperling","year":"2022","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103780_bib48","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5301\/jsrd.5000243","article-title":"Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis","volume":"2","author":"Morrisroe","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"10","key":"10.1016\/j.jpet.2025.103780_bib49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.31128\/AJGP-04-21-5939","article-title":"Medicinal cannabis in the treatment of chronic pain","volume":"50","author":"Henderson","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"10.1016\/j.jpet.2025.103780_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.892165","article-title":"Cannabinoid effect and safety in spasticity following stroke: a double-blind randomized placebo-controlled study","volume":"13","author":"Marinelli","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103780_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","article-title":"Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Riva","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103780_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jpet.2025.103780_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clin Rehabil"},{"issue":"5","key":"10.1016\/j.jpet.2025.103780_bib54","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00417-021-05533-1","article-title":"Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study","volume":"260","author":"Zloto","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jpet.2025.103780_bib55","series-title":"MIMS Online","article-title":"Sativex","year":"2022"},{"issue":"6","key":"10.1016\/j.jpet.2025.103780_bib56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40271-016-0173-0","article-title":"A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis","volume":"9","author":"Bethoux","year":"2016","journal-title":"Patient"},{"key":"10.1016\/j.jpet.2025.103780_bib57","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/B978-0-444-52007-4.00025-4","article-title":"Sleep disorders in multiple sclerosis","volume":"99","author":"Ferini-Strambi","year":"2011","journal-title":"Handb Clin Neurol"},{"issue":"13","key":"10.1016\/j.jpet.2025.103780_bib58","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1503\/cmaj.071178","article-title":"Adverse effects of medical cannabinoids: a systematic review","volume":"178","author":"Wang","year":"2008","journal-title":"CMAJ"},{"issue":"24","key":"10.1016\/j.jpet.2025.103780_bib59","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jpet.2025.103780_bib60","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archneur.1977.00500190056008","article-title":"Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis","volume":"34","author":"Sachais","year":"1977","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103780_bib61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2340\/16501977-0366","article-title":"Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes","volume":"41","author":"McCrory","year":"2009","journal-title":"J Rehabil Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:41Z","timestamp":1777420901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022356525402936"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103780","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103780"}}